

PRESS RELEASE

Stockholm, Sweden, 15 July 2020



The Board of directors exercises authorisation for repurchase of shares for the purpose of securing the company's commitments under the incentive programme

The Annual General Meeting of [Swedish Orphan Biovitrum AB \(publ\)](#) (Sobi™) on 13 May 2020, resolved – for the purpose of ensuring that the company can fulfil its commitments under the long-term incentive programme resolved by the Annual General Meeting – on a directed share issue of no more than 3,837,672 redeemable and convertible class C shares.

The meeting also resolved to authorise the Board of directors to resolve on the repurchase of all issued class C shares by an offer directed to all holders of class C shares. Repurchase under this authorisation may be made on one or several occasions until the Annual General Meeting in 2021 and at a price to no less than 100 per cent and no more than 105 per cent of the quotient value of the share.

The Board of directors has resolved to exercise the repurchase authorisation for the said purpose by repurchasing of all issued class C shares against payment of 100 per cent of the quotient value of the share, corresponding to approximately SEK 0.55 per share. Repurchase of the class C shares may be effected during the period 16 July – 13 November 2020.

The company currently holds 5,081,000 own common shares and no own class C shares. Subsequently to the effected repurchase of class C shares above, all repurchased class C shares are intended to be converted to common shares, where after the number of own common shares will amount to 8,918,672.

About Sobi™

Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. Sobi is providing sustainable access to innovative therapies in the areas of haematology, immunology and specialty indications. Today, Sobi employs approximately 1,400 people across Europe, North America, the Middle East, Russia and North Africa. In 2019, Sobi's revenues amounted to SEK 14.2 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. You can find more information about Sobi at sobi.com.

Contacts

Paula Treutiger, Head of Communication & Investor Relations
+ 46 733 666 599
paula.treutiger@sobi.com

Linda Holmström, Corporate Communication & Investor Relations
+ 46 708 734 095
linda.holmstrom@sobi.com

The information was released for public distribution on 15 July 2020 at 8:30 CEST.

Swedish Orphan Biovitrum AB (publ)

Postal address SE-112 76 Stockholm, Sweden
Phone: +46 8 697 20 00 | www.sobi.com